$ATXI
Avenue Therapeutics Inc

2022 Q3 Form 10-Q Financial Statement

#000141057822002605 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $469.0K $454.0K $1.055M
YoY Change -21.04% -27.13% 42.57%
% of Gross Profit
Research & Development $194.0K $151.0K $1.808M
YoY Change -30.22% -53.96% 600.78%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $194.0K $151.0K $1.808M
YoY Change -30.22% -53.96% 600.78%
Operating Profit -$663.0K -$605.0K -$2.863M
YoY Change -23.97% -36.38% 186.01%
Interest Expense $1.000K $1.000K $2.000K
YoY Change 0.0% -50.0%
% of Operating Profit
Other Income/Expense, Net $1.000K $1.000K $2.000K
YoY Change
Pretax Income -$662.0K -$604.0K -$2.861M
YoY Change -24.0% -36.35% 186.1%
Income Tax
% Of Pretax Income
Net Earnings -$662.0K -$604.0K -$2.861M
YoY Change -24.0% -36.35% 186.67%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$0.03 -$0.14
Diluted Earnings Per Share -$0.45 -$0.03 -$0.14
COMMON SHARES
Basic Shares Outstanding 22.13M 21.92M 20.96M
Diluted Shares Outstanding 1.466M 21.92M 20.96M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $217.0K $890.0K $1.833M
YoY Change -62.91% -20.61% 0.16%
Cash & Equivalents $217.0K $900.0K $1.800M
Short-Term Investments
Other Short-Term Assets $358.0K $115.0K $123.0K
YoY Change 1134.48% 64.29% 2.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $575.0K $1.005M $1.956M
YoY Change -16.42% -15.62% 0.82%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $575.0K $1.005M $1.956M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $575.0K $1.005M $1.956M
YoY Change -16.42% -15.62% 0.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $364.0K $293.0K $493.0K
YoY Change 80.2% 257.32% 252.14%
Accrued Expenses $250.0K $114.0K $304.0K
YoY Change -61.3% -75.59% -7.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $614.0K $407.0K $797.0K
YoY Change -27.59% -25.87% 69.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $614.0K $407.0K $797.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $614.0K $407.0K $797.0K
YoY Change -27.59% -25.87% 69.57%
SHAREHOLDERS EQUITY
Retained Earnings -$81.10M -$80.50M -$79.90M
YoY Change 6.57% 7.05%
Common Stock $81.09M $81.06M $81.02M
YoY Change 6.8% 6.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$39.00K $598.0K $1.159M
YoY Change
Total Liabilities & Shareholders Equity $575.0K $1.005M $1.956M
YoY Change -16.42% -15.62% 0.82%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$662.0K -$604.0K -$2.861M
YoY Change -24.0% -36.35% 186.67%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$554.0K -$943.0K -$1.930M
YoY Change 3.36% 34.52% 47.67%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -119.0K $0.00
YoY Change
NET CHANGE
Cash From Operating Activities -554.0K -943.0K -1.930M
Cash From Investing Activities
Cash From Financing Activities -119.0K $0.00
Net Change In Cash -673.0K -943.0K -1.930M
YoY Change 25.56% 34.52% 47.67%
FREE CASH FLOW
Cash From Operating Activities -$554.0K -$943.0K -$1.930M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21916005
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16556320
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21439242
dei Document Transition Report
DocumentTransitionReport
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16556320
dei Entity Central Index Key
EntityCentralIndexKey
0001644963
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22134784
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21089658
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3763000
CY2021Q4 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
90000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
115000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
107000
dei Entity File Number
EntityFileNumber
001-38114
dei Entity Registrant Name
EntityRegistrantName
AVENUE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4113275
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Gansevoort Street, 9th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10014
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
652-4500
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ATXI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22134784
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
890000
CY2022Q2 us-gaap Assets
Assets
1005000
CY2021Q4 us-gaap Assets
Assets
3960000
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
397000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
451000
CY2022Q2 atxi Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
10000
CY2021Q4 atxi Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
58000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
407000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
509000
CY2022Q2 us-gaap Liabilities
Liabilities
407000
CY2021Q4 us-gaap Liabilities
Liabilities
509000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22134784
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21089658
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
81060000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
80448000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80464000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76999000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
598000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3451000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1005000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3960000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
151000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
328000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1959000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
586000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
454000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
623000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1509000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1366000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-605000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-951000
us-gaap Operating Income Loss
OperatingIncomeLoss
-3468000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1952000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-604000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-949000
us-gaap Net Income Loss
NetIncomeLoss
-3465000
us-gaap Net Income Loss
NetIncomeLoss
-1947000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21916005
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16556320
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21439242
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16556320
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1159000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
43000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-604000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
598000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3451000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
612000
us-gaap Net Income Loss
NetIncomeLoss
-3465000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
598000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1475000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
116000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-949000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
642000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2359000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
230000
us-gaap Net Income Loss
NetIncomeLoss
-1947000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
642000
us-gaap Profit Loss
ProfitLoss
-3465000
us-gaap Profit Loss
ProfitLoss
-1947000
us-gaap Share Based Compensation
ShareBasedCompensation
612000
us-gaap Share Based Compensation
ShareBasedCompensation
230000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
90000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-43000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-54000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-441000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-48000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
104000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2873000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2011000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2873000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2011000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3763000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3132000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
890000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1121000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1159000
CY2022Q3 atxi Ratio Of Number Of Votes Per Share
RatioOfNumberOfVotesPerShare
99
CY2022Q3 atxi Percentage Of Voting Power Of Companys Capital Stock Held By Holders Signed Written Consent
PercentageOfVotingPowerOfCompanysCapitalStockHeldByHoldersSignedWrittenConsent
0.73
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80500000
CY2022Q1 atxi Number Of No Votes
NumberOfNoVotes
14
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
571230
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1389910
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
293000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
304000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
15000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
24000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
89000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
123000
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
397000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
451000

Files In Submission

Name View Source Status
0001410578-22-002605-index-headers.html Edgar Link pending
0001410578-22-002605-index.html Edgar Link pending
0001410578-22-002605.txt Edgar Link pending
0001410578-22-002605-xbrl.zip Edgar Link pending
atxi-20220630.xsd Edgar Link pending
atxi-20220630x10q.htm Edgar Link pending
atxi-20220630xex10d1.htm Edgar Link pending
atxi-20220630xex31d1.htm Edgar Link pending
atxi-20220630xex31d2.htm Edgar Link pending
atxi-20220630xex32d1.htm Edgar Link pending
atxi-20220630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atxi-20220630_lab.xml Edgar Link unprocessable
atxi-20220630x10q_htm.xml Edgar Link completed
atxi-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atxi-20220630_cal.xml Edgar Link unprocessable
atxi-20220630_def.xml Edgar Link unprocessable